INcreasing Statin Prescribing in HIV Behavioral Economics REsearch
Public ClinicalTrials.gov record NCT03687060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Behavioral Economics and Implementation Research to Reduce Cardiovascular Risk in HIV-Infected Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cardiovascular disease is a major cause of morbidity and mortality among people living with HIV. Recent studies have demonstrated that patients with HIV experience a 50-100% increased risk of myocardial infarction and stroke compared to HIV-uninfected persons. They also face higher risks of stroke, sudden death, and heart failure. However, evidence-based statin therapy-which is safe in this population and highly effective at reducing cardiovascular risk-is under-prescribed. The investigators propose a multi-level intervention to increase evidence-based statin prescribing by addressing barriers at these levels. The implementation intervention includes two strategies: (1) tailored education at the leadership, provider, and patient levels, and (2) behavioral economics-informed feedback for providers.
Study identification
- NCT ID
- NCT03687060
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Interventions
- Knowledge assessment Behavioral
- Education Intervention Behavioral
- Provider Feedback Behavioral
Behavioral
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 3, 2019
- Primary completion
- Nov 30, 2023
- Completion
- Feb 29, 2024
- Last update posted
- Oct 1, 2023
2019 – 2024
United States locations
- U.S. sites
- 8
- U.S. states
- 1
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| JWCH Institute | Commerce | California | 90040 | — |
| Antelope Valley Health Center | Lancaster | California | 93535 | — |
| Watts Health Center | Los Angeles | California | 90002 | — |
| Oasis Clinic | Los Angeles | California | 90059 | — |
| To Help Everyone Health and Wellness Centers | Los Angeles | California | 90062 | — |
| Venice Family Clinic | Santa Monica | California | 90405 | — |
| Olive View-UCLA Medical Center | Sylmar | California | 91342 | — |
| Tarzana Treatment Centers, Inc. | Tarzana | California | 91356 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03687060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03687060 live on ClinicalTrials.gov.